Cardioprotective Effects of Pioglitazone in Type 2 Diabetes.
Diabetes Spectr
; 34(3): 243-247, 2021 Aug.
Article
em En
| MEDLINE
| ID: mdl-34511850
ABSTRACT
Antidiabetic medications that improve glycemic control as well as cardiovascular outcomes will be the mainstay of treatment for type 2 diabetes moving forward. This article reviews the beneficial effects of the thiazolidinedione pioglitazone of ameliorating hyperglycemia and improving cardiovascular risk factors. While the newer sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide 1 receptor agonist drug classes have confirmed cardiovascular benefits, pioglitazone also has been shown to reduce major adverse cardiovascular events, in both people with type 2 diabetes and nondiabetic subjects with insulin resistance. Adverse effects associated with pioglitazone can be mitigated by its use at a lower dose and in combination with antidiabetic agents from other drug classes.
Texto completo:
1
Base de dados:
MEDLINE
Idioma:
En
Revista:
Diabetes Spectr
Ano de publicação:
2021
Tipo de documento:
Article